-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia

doi:10.3748/wjg.v12.i34.5473

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 34

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3281)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

351

HTML

2514

Figures (1-1)

195

Tables (1-4)

221

Sum=3281

Sep 14, 2006 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Sep 14, 2006; 12(34): 5473-5478
Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5473

Table 3 Frequency distributions and Odds Ratio for risk of atrophy and intestinal metaplasia or gastric adenocarcinoma in -765 C carriers

Pathology	Genotype n (%)		OR (95% CI)		OR²(95% Cl)
Pathology	GG	C carrier			OR²(95% Cl)
Controls	130 (62)	80 (38)	OR (95% CI)		1.00 (Reference)	1.00 (Reference)¹
Atrophy or intestinal metaplasia	27 (73)	10 (27)	0.60 (0.28-1.31)	0.95 (0.91-0.99)¹	1.00 (Reference)
Gastric adenocarcinoma	36 (49)	37 (51)	1.67 (0.98-2.86)	1.45 (0.84-2.64)¹	2.67 (1.03-6.93)

¹ OR adjusted for age and gender in a multivariate logistic regression analysis;

² OR adjusted for age and gender in a multivariate logistic regression analysis for the progression of atrophy or intestinal metaplasia into gastric cancer.

Citation: Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12(34): 5473-5478
URL: https://www.wjgnet.com/1007-9327/full/v12/i34/5473.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i34.5473